Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system - Report - MDSpire
Advertisement
Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system
Interstitial Lung Disease Linked to Anticancer Drugs in Breast, Ovarian, and Prostate Cancers
Overview
This study analyzes interstitial lung disease (ILD) reports associated with 65 anticancer agents in breast, ovarian, and prostate cancers, revealing significant ILD reporting associations, particularly with trastuzumab deruxtecan. The findings highlight the importance of monitoring ILD in patients receiving these therapies.
Background
Interstitial lung disease (ILD) is a serious adverse effect of anticancer therapies, impacting patient quality of life and associated with high mortality rates. Understanding ILD reporting associations among different antineoplastic agents is crucial for optimizing patient management and safety. This study leverages the FDA Adverse Event Reporting System to elucidate these associations in sex hormone-sensitive solid tumors.
Data Highlights
Agent
Reporting Odds Ratio
Trastuzumab deruxtecan (T-DXd)
Highest adjusted reporting association
Darolutamide
Elevated ILD reporting association
Fulvestrant
Elevated ILD reporting association
Key Findings
Trastuzumab deruxtecan showed the highest ILD reporting association among analyzed agents.
Older age and lower body weight were independently associated with increased ILD reporting.
Death-recorded ILD reports had a shorter median time-to-onset compared to non-death-recorded reports.
Some sex hormone-pathway agents exhibited underemphasized ILD signals.
Exploratory analyses indicated varying ILD reporting associations across different antineoplastic agents.
Clinical Implications
Clinicians should be vigilant in monitoring for ILD in patients treated with specific anticancer agents, particularly trastuzumab deruxtecan. Patient factors such as age and body weight should be considered when assessing ILD risk.
Conclusion
The study underscores the variability of ILD reporting associations among anticancer agents, emphasizing the need for careful monitoring and further research to confirm these findings.
